Rhumbline Advisers Has $115,000 Holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX)

Rhumbline Advisers grew its position in G1 Therapeutics, Inc. (NASDAQ:GTHX) by 5,136.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,632 shares of the company’s stock after purchasing an additional 49,665 shares during the quarter. Rhumbline Advisers owned about 0.10% of G1 Therapeutics worth $115,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of G1 Therapeutics during the first quarter worth approximately $58,000. Capstone Investment Advisors LLC acquired a new stake in G1 Therapeutics in the fourth quarter valued at about $76,000. Bank of New York Mellon Corp bought a new position in G1 Therapeutics in the 2nd quarter valued at approximately $304,000. Panagora Asset Management Inc. bought a new stake in shares of G1 Therapeutics during the second quarter worth about $404,000. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of G1 Therapeutics by 20.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 377,858 shares of the company’s stock worth $1,632,000 after purchasing an additional 64,790 shares during the period. Institutional investors and hedge funds own 24.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GTHX. Needham & Company LLC reiterated a “hold” rating on shares of G1 Therapeutics in a research report on Wednesday, August 7th. Wedbush lowered shares of G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. Finally, HC Wainwright cut G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th.

G1 Therapeutics Stock Performance

NASDAQ GTHX opened at $7.15 on Tuesday. The company has a market capitalization of $373.81 million, a PE ratio of -11.53 and a beta of 1.66. The company has a debt-to-equity ratio of 1.34, a quick ratio of 2.12 and a current ratio of 2.48. G1 Therapeutics, Inc. has a 52-week low of $1.08 and a 52-week high of $7.19. The company has a 50-day simple moving average of $6.43 and a 200 day simple moving average of $4.64.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. G1 Therapeutics had a negative net margin of 76.93% and a negative return on equity of 136.98%. The company had revenue of $16.55 million for the quarter, compared to analysts’ expectations of $15.88 million. On average, research analysts predict that G1 Therapeutics, Inc. will post -0.45 EPS for the current year.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.